首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF7 |
| Uniprot No | P21781 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-194aa |
| 氨基酸序列 | CNDMTPEQMATNVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDK RGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKK ECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKK EQKTAHFLPMAIT |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FGF7(重组蛋白)的参考文献概要，按研究领域分类整理：
1. **文献名称**：*"Recombinant human keratinocyte growth factor (rHuKGF) stimulates epithelial regeneration in experimental colitis"*
**作者**：Podolsky DK 等
**摘要**：该研究证实重组FGF7(KGF)通过激活下游信号通路(如MAPK)促进结肠上皮细胞增殖，显著加速实验性结肠炎小鼠模型的黏膜修复，提示其在炎症性肠病治疗中的潜力。
2. **文献名称**：*"KGF promotes tumorigenic potential by regulating EMT-related genes in colorectal cancer"*
**作者**：Zhang Y 等
**摘要**：研究发现肿瘤微环境中FGF7过表达可通过诱导上皮-间质转化(EMT)，增强结直肠癌细胞的迁移和侵袭能力，提示靶向FGF7信号可能成为抑制肿瘤转移的新策略。
3. **文献名称**：*"Topical application of recombinant FGF7 enhances diabetic wound healing via dermal matrix reconstruction"*
**作者**：Sugimoto H 等
**摘要**：通过糖尿病小鼠模型证实，局部使用重组FGF7可显著增加真皮层胶原蛋白沉积，促进血管新生，缩短伤口愈合时间约40%，为糖尿病慢性溃疡治疗提供了实验依据。
*注：以上为示例性内容，实际文献检索建议通过PubMed或Web of Science使用关键词 "recombinant FGF7/KGF" + 具体研究领域(如wound healing/cancer therapy)获取最新研究。*
**Background of Recomcombinant FGF7 Protein**
Fibroblast Growth Factor 7 (FGF7), also known as keratinocyte growth factor (KGF), is a paracrine-acting protein belonging to the FGF family, specifically the FGF subfamily 7. It is primarily secreted by mesenchymal cells and plays a critical role in epithelial cell proliferation, differentiation, and tissue repair. Recombinant FGF7 is engineered through genetic expression systems (e.g., *E. coli* or mammalian cells) to produce a bioactive form identical to the native human protein. Structurally, it consists of 194 amino acids with a molecular weight of ~22–24 kDa and binds selectively to the FGFR2 IIIb receptor isoform, activating downstream signaling pathways such as MAPK and PI3K-Akt.
FGF7 is pivotal in maintaining epithelial homeostasis and regeneration. It promotes wound healing by stimulating keratinocyte migration and proliferation, making it a therapeutic candidate for conditions like mucositis, skin ulcers, and corneal injuries. Additionally, it supports alveolar epithelial repair in lung diseases and regulates hair follicle development. Dysregulation of FGF7 signaling is implicated in pathologies, including fibrosis and certain cancers, where its overexpression may drive tumor progression.
Pharmaceutically, recombinant FGF7 has been explored in clinical settings. For instance, palifermin, a recombinant human KGF, is FDA-approved to mitigate severe oral mucositis in chemotherapy/radiotherapy patients. Research also highlights its potential in regenerative medicine, such as enhancing stem cell expansion or tissue-engineered grafts.
Quality-controlled production ensures high purity, stability, and bioactivity, enabling reproducible applications in research and therapy. Despite challenges in delivery and targeting, recombinant FGF7 remains a key molecule in understanding epithelial biology and developing targeted regenerative therapies.
×
